Parkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations

2 SOURCES CONFIRMED · FIRST SEEN 2026-10-06 14:31 UTC

EXHIBIT · mmx.prnewswire.com

KINDNews

DIRECTION■ Mixed

SOURCES2

ENTITIES2

STORY SIZE2 RECORDS

FIRST SEEN2026-10-06 14:31 UTC

LAST UPDATE2026-10-06 14:31 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

Forecast reports on Parkinson's growth are marketing for research firms; AbbVie approval is the only hard fact and touches a large neuro market.

Parkinson's pipeline expands, but report is vendor marketing

CATALYST TO WATCH

JUVMO launch uptake and payer coverage

MAIN RISK

Forecast is promotional, not verified data

FULL DISPATCH

The Parkinson's disease market is expected to grow steadily, driven by the recent approval of AbbVie's JUVMO along with the rising prevalence of the disease, particularly among the aging population. Increasing disease awareness, improved diagnosis, and advances in symptomatic and...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

UPDATED 2 TIMES · FIRST 2026-10-06 14:31 UTC · LAST 2026-10-06 14:31 UTC

2026-10-06 14:31 UTCNewsParkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic InnovationsCURRENT RECORD

2026-10-06 14:31 UTCNewsParkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDEli Lilly · LLY

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED

№ 01prnewswireprnewswire.com · PRIMARY2026-10-06 14:31 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

→CORRELATIONshares Healthcare
OPCH shares jump 34% as CD&R, McKesson agree to $5.8B takeover (OPCH:NASDAQ)2026-10-06 12:33 UTC

→CORRELATIONshares Healthcare
A $1B special dividend features in Indivior (INDV)'s revised merger valuation details.2026-10-06 14:10 UTC

→CORRELATIONshares Healthcare
Lycia seeks IPO for antibody degraders as TRexBio, Retension set terms2026-10-06 08:21 UTC

→CORRELATIONshares Healthcare
Curaleaf Files Update to Offering Circular2026-10-06 15:25 UTC

→CORRELATIONshares Healthcare
Saluda Medical Expands Access to First and Only FDA-Approved Closed-Loop Surgical Paddle Lead with Full US Commercial Release of CAP24™2026-10-06 15:27 UTC

→CORRELATIONshares Healthcare
M&A gains ground as strategic revenue driver2026-10-06 15:23 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.